Therapeutic uses of anti- 4-integrin (anti-VLA-4) antibodies in multiple sclerosis

VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells

(2014) Tilman Schneider-Hohendorf et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?

(2014) Gary R Cutter et al.   Multiple Sclerosis Journal

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study

(2014) P. O'Connor et al.   NEUROLOGY

Maraviroc and JC Virus–Associated Immune Reconstitution Inflammatory Syndrome

(2014) Paul S. Giacomini et al.   NEW ENGLAND JOURNAL OF MEDICINE

α4-integrins control viral meningoencephalitis through differential recruitment of T helper cell subsets

(2014) Veit Rothhammer et al.   Acta Neuropathologica Communications

A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification

(2013) Peter Lee et al.   JOURNAL OF CLINICAL VIROLOGY

READING BETWEEN THE LINES: A CASE SERIES IN PRIMARY READING EPILEPSY

(2013) Roisin Lonergan et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients

(2013) N. Schwab et al.   NEUROLOGY

Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study

(2013) Anna Bellizzi et al.   Virology Journal

Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system

(2012) Catherine Larochelle et al.   BRAIN

Drug-Induced PML: A Global Agenda for a Global Challenge

(2012) M Vinhas de Souza et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Update on Progressive Multifocal Leukoencephalopathy

(2012) Israel Steiner et al.   Current Neurology and Neuroscience Reports

Neuroinflammation

(2012) Heinz Wiendl   CURRENT OPINION IN NEUROLOGY

Immune Therapy of Multiple Sclerosis - Future Strategies

(2012) Sven G. Meuth et al.   CURRENT PHARMACEUTICAL DESIGN

Crohn's disease

(2012) Daniel C Baumgart et al.   LANCET

Progressive multifocal leukoencephalopathy in a patient with transitory lymphopenia

(2012) J. N. Chabwine et al.   NEUROLOGY

Fatal PML associated with efalizumab therapy: Insights into integrin  L 2 in JC virus control

(2012) N. Schwab et al.   NEUROLOGY

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Laminin-411 Is a Vascular Ligand for MCAM and Facilitates TH17 Cell Entry into the CNS

(2012) Ken Flanagan et al.   PLoS One

Capture, crawl, cross: the T cell code to breach the blood–brain barriers

(2012) Britta Engelhardt et al.   TRENDS IN IMMUNOLOGY

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Advances in the management of PML: Focus on natalizumab

(2011) R. FOX   CLEVELAND CLINIC JOURNAL OF MEDICINE

HIV-associated PML: Changing epidemiology and clinical approach

(2011) D. M. SIMPSON   CLEVELAND CLINIC JOURNAL OF MEDICINE

Immunological and clinical consequences of treating a patient with natalizumab

(2011) Nicholas Schwab et al.   Multiple Sclerosis Journal

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

(2011) Stephen Sawcer et al.   NATURE

Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis

(2011) Saskia Thomas et al.   INFLAMMOPHARMACOLOGY

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY

Opportunistic infections and other risks with newer multiple sclerosis therapies

(2009) Joseph R. Berger et al.   ANNALS OF NEUROLOGY

Incidence and Outcome of Progressive Multifocal Leukoencephalopathy over 20 Years of the Swiss HIV Cohort Study

(2009) Nina Khanna et al.   CLINICAL INFECTIOUS DISEASES

CD8+ T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability

(2009) Nico Melzer et al.   FASEB JOURNAL

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

(2009) Kenneth R Carson et al.   LANCET ONCOLOGY

C-C chemokine receptor 6–regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE

(2009) Andrea Reboldi et al.   NATURE IMMUNOLOGY

Iatrogenic immunosuppression with biologics in MS: Expecting the unexpected?

(2009) O. Stuve et al.   NEUROLOGY

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

(2009) B. O. Khatri et al.   NEUROLOGY

Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: Implications for multiple sclerosis

(2008) Eva Herrero-Herranz et al.   NEUROBIOLOGY OF DISEASE